Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


Improving cancer drug research technology wins nanotechnology startup $300K grant

12:30 pm by | 0 Comments

R&D pharma spending North Carolina

As innovative new cancer therapies become more advanced and targeted, the tools used in researching and developing them should be improved and innovated too.

Indiana-based Tymora Analytical Operations LLC is doing that by developing nanotechnology-based research products for life sciences R&D. The PolyMAC technology that it commercialized earlier this year could help researchers better assess whether drugs being developed actually hit their targets.

President and chief technology officer Anton Iliuk said some diseases, especially cancer, start from abnormal phosphorylation of proteins. Tymora’s technology aims to enrich and isolate those modified proteins to give researchers a better way to find new targets for drugs. In another application, the technology could potentially help researchers identify whether their drugs are actually hitting their targets and working after prolonged treatment.

Advertisement

“Everyone with the current technology can see the tip of the iceberg, but the most important proteins that are modified exist in very low amounts, so you have to have more sensitivity and specificity,” Iliuk said. “We’re also trying to improve reproducibility of analysis so you can compare different samples to each other.”

The startup has just received a $300,000 SBIR grant from the National Institutes of Health, which it will use to strengthen its PolyMAC product and build on the foundation of the technology to develop new products. Previously, Tymora received at least $320,000 in grants from the NIH and Purdue’s Emerging Innovations Fund.

Founded in 2010 by two research scientists at Purdue University, the startup now calls Purdue Research Park its home. It launched its PolyMAC product earlier this year and is selling to cancer centers, researchers and some life sciences companies, Iliuk said.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Deanna Pogorelc

By Deanna Pogorelc MedCity News

Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.
More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement